THRB

Across TCGA pan-cancer cohorts, THRB Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated THRB data layer compared with 20 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher THRB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated THRB expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

BRCA, LGG, and UCEC are the cancer types where THRB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	II,III,IV	0.110	0.565	.011	18	view →
LGG	OS	Median	All	0.207	0.810	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.866	0.304	.027	12	view →
LUSC	OS	Median	All	0.307	0.728	.028	6	view →
LUAD	OS	Median	All	0.468	0.790	.022	6	view →
COAD	OS	Median	III,IV	0.140	0.696	.027	3	view →
GBM	OS	Median	All	1.000	0.257	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

THRB–BRCA (OS)

Open the BRCA breakdown →